Journal article
Germline miRNA DNA variants and the risk of colorectal cancer by subtype
NM Lindor, MC Larson, MS DeRycke, SK McDonnell, S Baheti, ZC Fogarty, AK Win, JD Potter, DD Buchanan, M Clendenning, PA Newcomb, G Casey, S Gallinger, L Le Marchand, JL Hopper, MA Jenkins, EL Goode, SN Thibodeau
Genes Chromosomes and Cancer | WILEY | Published : 2017
DOI: 10.1002/gcc.22420
Abstract
MicroRNAs (miRNAs) regulate up to one-third of all protein-coding genes including genes relevant to cancer. Variants within miRNAs have been reported to be associated with prognosis, survival, response to chemotherapy across cancer types, in vitro parameters of cell growth, and altered risks for development of cancer. Five miRNA variants have been reported to be associated with risk for development of colorectal cancer (CRC). In this study, we evaluated germline genetic variation in 1,123 miRNAs in 899 individuals with CRCs categorized by clinical subtypes and in 204 controls. The role of common miRNA variation in CRC was investigated using single variant and miRNA-level association tests. T..
View full abstractRelated Projects (2)
Grants
Awarded by National Cancer Institute
Funding Acknowledgements
Supported by: National Cancer Institute and through cooperative agreements with the following CCFR centers, Grant number: UM1 CA167551; Australasian Colorectal Cancer Family Registry, Grant numbers: U01 CA074778 and U01/U24 CA097735; Mayo Clinic Cooperative Family Registry for Colon Cancer Studies, Grant number: U01/U24 CA074800; Ontario Familial Colorectal Cancer Registry, Grant number: U01/U24 CA074783; Seattle Colorectal Cancer Family Registry, Grant number: U01/U24 CA074794; University of Hawaii Colorectal Cancer Family Registry, Grant number: U01/U24 CA074806; USC Consortium Colorectal Cancer Family Registry, Grant number: U01/U24 CA074799; Cancer Surveillance System of the Fred Hutchinson Cancer Research Center (Seattle CCFR research), Grant numbers: N01-CN-67009 (1996-2003) and N01-PC-35142 (2003-2010); from the Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute with additional support from the Fred Hutchinson Cancer Research Center; Grant numbers: HHSN2612013000121 (2010-2017); Hawai'i Department of Health as part of the statewide cancer reporting program mandated by Hawai'i Revised Statutes (the collection of cancer incidence data for the State of Hawai'i); National Cancer Institute's Surveillance, Epidemiology and End Results Program (SEER), Grant numbers: N01-PC-67001 (1996-2003) and N01-PC-35137 (2003-2010); University of Hawai'i, Grant numbers: HHSN26120100037C (2010-2013) and HHSN261201300009I (2010-current); State of Hawai'i, Department of Health, the National Cancer Institute; SEER Program or their Contractors and Subcontractors is not intended nor should be inferred;. California Department of Public Health (California Health and Safety Code Section 103885); National Cancer Institute's Surveillance, Epidemiology and End Results Program (Cancer Prevention Institute of California), Grant number: HHSN261201000140C; University of Southern California, Grant number: HHSN261201000035C; Public Health Institute, HHSN261201000034C; Centers for Disease Control and Prevention's National Program of Cancer Registries (California Department of Public Health), Grant number: U58DP003862-01; State of California, Department of Public Health the National Cancer Institute; Centers for Disease Control and Prevention or their Contractors and Subcontractors is not intended nor should be inferred; National Cancer Institute or any of the collaborating centers in the Colon Cancer Family Registry (CCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the CCFR.